Tech Company Financing Transactions

Apollo Therapeutics Funding Round

On 9/7/2023, Apollo Therapeutics landed $226.5 million in Series C funding from Patient Square Capital, M&G Investments and Rock Springs Capital.

Transaction Overview

Announced On
9/7/2023
Transaction Type
Venture Equity
Amount
$226,500,000
Round
Series C
Proceeds Purpose
Proceeds will be used to advance pipeline programmes through clinical development and further fund Apollo's drug discovery and development activities based on breakthroughs in basic medical research at its partner institutions. Capital raised will also be used to licence or acquire additional clinical stage programmes that "meet strict selection criteria".

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3rd Floor 22 Station Road
Cambridge, England, CB1 2JD
UK
Phone
Undisclosed
Email Address
Overview
Apollo Therapeutics is a biopharmaceutical company rapidly advancing a robust pipeline of potentially transformative therapeutic programs based on breakthrough discoveries. Through deep relationships with world-leading universities and scientists, the company identifies programs with strong biological hypotheses and potential to become meaningful new treatment options. Apollo's portfolio-based model combines a centralized team of drug development 'architects' and subject matter experts who are able to rigorously evaluate therapeutic programs in an objective, data-driven manner -- prioritizing critical experiments to de-risk programs early. This capital efficiency allows Apollo to focus on scaling a robust and potentially transformative pipeline, with over 15 therapeutic programs in development today across oncology, major inflammatory disorders and rare disease.
Profile
Apollo Therapeutics LinkedIn Company Profile
Social Media
Apollo Therapeutics Company Twitter Account
Company News
Apollo Therapeutics News
Facebook
Apollo Therapeutics on Facebook
YouTube
Apollo Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Richard Mason
  Richard  Mason LinkedIn Profile  Richard  Mason Twitter Account  Richard  Mason News  Richard  Mason on Facebook
Chief Financial Officer
Jamie Heath
  Jamie Heath LinkedIn Profile  Jamie Heath Twitter Account  Jamie Heath News  Jamie Heath on Facebook
Chief Scientific Officer
Richard Butt
  Richard Butt LinkedIn Profile  Richard Butt Twitter Account  Richard Butt News  Richard Butt on Facebook


 

 

Browse more venture capital transactions:

Prev: 9/7/2023: ActiveFence venture capital transaction
Next: 9/7/2023: Ello venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on tech company VC transactions. VC transactions reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary